LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
Author:
Jones Bryan E.ORCID, Brown-Augsburger Patricia L., Corbett Kizzmekia S., Westendorf Kathryn, Davies Julian, Cujec Thomas P., Wiethoff Christopher M., Blackbourne Jamie L., Heinz Beverly A., Foster Denisa, Higgs Richard E., Balasubramaniam Deepa, Wang Lingshu, Bidshahri Roza, Kraft Lucas, Hwang Yuri, Žentelis Stefanie, Jepson Kevin R., Goya Rodrigo, Smith Maia A., Collins David W., Hinshaw Samuel J., Tycho Sean A., Pellacani Davide, Xiang Ping, Muthuraman Krithika, Sobhanifar Solmaz, Piper Marissa H., Triana Franz J., Hendle Jorg, Pustilnik Anna, Adams Andrew C., Berens Shawn J., Baric Ralph S., Martinez David R., Cross Robert W., Geisbert Thomas W., Borisevich Viktoriya, Abiona Olubukola, Belli Hayley M., de Vries Maren, Mohamed Adil, Dittmann Meike, Samanovic Marie, Mulligan Mark J., Goldsmith Jory A., Hsieh Ching-Lin, Johnson Nicole V., Wrapp Daniel, McLellan Jason S., Barnhart Bryan C., Graham Barney S., Mascola John R., Hansen Carl L., Falconer EsterORCID
Abstract
AbstractSARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection.One Sentence SummaryLY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.
Publisher
Cold Spring Harbor Laboratory
Reference24 articles.
1. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future 2. linical features of patients infected with 2019 novel coronavirus in Wuhan, China;The Lancet,2020 3. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses 4. E. J. Williamson , A. J. Walker , K. Bhaskaran , S. Bacon , C. Bates , C. E. Morton , H. J. Curtis , A. Mehrkar , D. Evans , P. Inglesby , J. Cockburn , H. I. McDonald , B. MacKenna , L. Tomlinson , I. J. Douglas , C. T. Rentsch , R. Mathur , A. Y. S. Wong , R. Grieve , D. Harrison , H. Forbes , A. Schultze , R. Croker , J. Parry , F. Hester , S. Harper , R. Perera , S. J. W. Evans , L. Smeeth , B. Goldacre , OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature, (2020). 5. Structural basis of receptor recognition by SARS-CoV-2;Nature,2020
Cited by
123 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|